Biomea Fusion, Inc. (BMEA)
2.03
+0.12
(+6.28%)
USD |
NASDAQ |
Sep 04, 16:00
2.03
0.00 (0.00%)
After-Hours: 20:00
Biomea Fusion Debt to Equity Ratio : 0.0723 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0723 |
| March 31, 2026 | 0.0662 |
| December 31, 2025 | 0.0538 |
| September 30, 2025 | 0.4402 |
| June 30, 2025 | 0.2564 |
| March 31, 2025 | 0.2758 |
| December 31, 2024 | 0.1701 |
| September 30, 2024 | 0.1259 |
| June 30, 2024 | 0.0995 |
| March 31, 2024 | 0.082 |
| December 31, 2023 | 0.0608 |
| September 30, 2023 | 0.0606 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.0567 |
| March 31, 2023 | 0.1605 |
| December 31, 2022 | 0.0211 |
| September 30, 2022 | 0.0186 |
| June 30, 2022 | 0.0171 |
| March 31, 2022 | 0.0165 |
| December 31, 2021 | 0.0159 |
| September 30, 2021 | 0.0156 |
| June 30, 2021 | 0.0151 |
| March 31, 2021 | 252.98 |
| December 31, 2020 | 10.83 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| REGENXBIO, Inc. | 3.49 |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 36.87M |
| Total Liabilities (Quarterly) | 24.74M |
| Shareholders Equity (Quarterly) | 12.14M |
| Current Ratio | 3.475 |
| Net Debt Paydown Yield | 1.32% |